Autodesk (NASDAQ:ADSK) had its price target lowered by analysts at Rosenblatt Securities from $375.00 to $330.00. They now have a "buy" rating on the stock.
Autodesk and U.S. Paralympian, CEO & founder of BioDapt, Mike Schultz, announce partnership to advance next-generation prosthetics
Autodesk (NASDAQ:ADSK) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
????????? 3D ?????? ?????????2032??301?2,000?????????:CAGR 26.1%???? [CNET News]
Autodesk (NASDAQ:ADSK) had its price target lowered by analysts at Stifel Nicolaus from $375.00 to $285.00. They now have a "buy" rating on the stock.